ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

06 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

31 Jul 2024 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

31 Jul 2024 05:30:00 By Nasdaq GlobeNewswire

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

02 Jun 2024 10:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

29 May 2024 09:00:01 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 16:00:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Allison Dillon as Chief Business Officer

07 May 2024 09:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer

30 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

24 Apr 2024 10:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

09 Apr 2024 17:30:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

07 Mar 2024 16:03:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

13 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

ALX Oncology Announces November Investor Conference Participation

01 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

10 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Pricing of Public Offering

05 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Proposed Public Offering

04 Oct 2023 16:10:18 By Nasdaq GlobeNewswire

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

03 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

02 Oct 2023 16:05:00 By Nasdaq GlobeNewswire